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Abstract 12 
 13 
Analysis of the human genome revealed that only 1.2% encoded for proteins, which raised 14 
questions regarding the biological significance of the remaining genome. We now know that 15 
approximately 80% of the genome serves at least one biochemical function within the cell. A 16 
portion of this 80% consists of a family of non-coding regulatory RNAs, one important 17 
member being microRNAs (miRNAs). miRNAs can be detected in tissues and biofluids, 18 
where miRNAs in the latter can be bound to proteins or encapsulated within lipid vesicles 19 
such as exosomes. Gestational diabetes mellitus (GDM) is a complication of pregnancy, 20 
which has harmful health impacts on both the fetus as well as the mother. The incidence of 21 
GDM worldwide varies, but reached 18% in the HAPO cohort using the new International 22 
Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria. Not only has GDM 23 
been associated with increased risks of further complications during pregnancy, but also pose 24 
long-term risks for both the mother and the baby. Thus, understanding the pathophysiology of 25 
GDM is important from a public health perspective. Literature has demonstrated that GDM is 26 
associated with elevated levels of circulating exosomes in maternal circulation. However, 27 
there is a paucity of data defining the expression, role, and diagnostic utility of miRNAs 28 
in GDM. This review briefly summarizes recent advances in the function and quantification 29 
of intracellular and extracellular miRNAs in GDM. 30 
 31 
 32 
  33 
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Introduction 34 
 35 
During normal pregnancy, glucose intolerance gradually increases during the second and third 36 
trimesters of pregnancy to ensure adequate nutrient supply for the fetus [1]. A pregnant 37 
mother with acquired or chronic insulin resistance is not able to compensate for the increased 38 
circulating glucose concentrations due to β-cell dysfunction. The resulting maternal 39 
hyperglycaemia increases the risk of disease for both the mother and her offspring. Therefore, 40 
any degree of abnormal glucose metabolism diagnosed during pregnancy is termed 41 
gestational diabetes mellitus (GDM). 42 
GDM accounts for 90% of hyperglycaemic complications of pregnancy, affects 3-8% 43 
of all pregnancies and has a recurrence rate of 35-80% [1]. GDM can lead to morbidity and 44 
mortality in both the mother and the infant, which includes pre-eclampsia, subsequent 45 
development of diabetes mellitus type 2 (DM2) in the mother, fetal macrosomia, congenital 46 
malformation, perinatal mortality and obesity [2]. 47 
 Due to the comorbidities and risks associated with GDM pregnancies, it has become 48 
apparent that screening in the first trimester or early-second trimester of pregnancy is critical 49 
in metabolic disorders such as GDM [3]. Early diagnosis is essential in reducing GDM 50 
associated complications for both the mother and the fetus, by implementing treatments which 51 
normalize blood glucose levels. However, the current two-step approach screening method 52 
based on plasma glucose measurement identify women at a later stage of GDM (24-28 weeks 53 
of gestation) [4]. This means that treatment cannot start until 32 weeks of gestation, which 54 
already presents a high risk of fetal morbidity and mortality. Consequently, many researchers 55 
are investigating potential biomarkers present in the blood to accurately diagnose GDM 56 
earlier than 24-28 weeks (e.g. 16-19 weeks of gestation) [5]. microRNAs (miRNAs) show 57 
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great potential as early-trimester biomarkers for GDM, as they are highly stable in body fluids 58 
and are accessible from maternal fluids throughout gestation [6]. 59 
 Dysregulation of miRNA expression has been associated with metabolic disorders in 60 
insulin secreted as well as insulin-targeted tissues and cells [7]. Furthermore, miRNAs have 61 
been associated with GDM and its resulting health complications [8, 9]. Research in miRNA 62 
profiling will provide valuable information in identifying unique and sensitive biomarkers in 63 
body fluids to utilize as diagnostics or therapeutics in GDM. This can prevent adverse 64 
pregnancy outcomes and reduce healthcare costs associated with GDM. This review aims to 65 
provide an overview of recent advances in extracellular and intracellular miRNAs involved in 66 
GDM pathogenesis. 67 
 68 
miRNA biogenesis and function  69 
 70 
Biogenesis: 71 
miRNAs are small non-coding RNA fragments approximately 22 nucleotides in length [10]. 72 
In the initial stage of miRNA biogenesis, intergenic regions and introns where miRNAs 73 
reside, are transcribed by RNA polymerase II and III [11, 12]. This produces a long transcript 74 
called primary miRNA (pri-miRNA) that is greater than 70 nucleotides in length [13]. Within 75 
the nucleus, this pri-miRNA folds into a structure containing a stem-loop with single stranded 76 
5’ and 3’ RNA ends. The proteins Drosha and its cofactor DGRC8 bind and cleave the pri-77 
miRNA at the stem-loop base, discarding the single stranded RNA ends [14, 15]. 78 
Subsequently, this stem loop structure (termed a pre-miRNA) is exported into the cytoplasm 79 
by exportin 5 [16]. 80 
Within the cytoplasm, the pre-miRNA is further processed by protein Dicer, cleaving 81 
the terminal loop [17]. The remaining double stranded RNA is loaded into a multi-protein 82 
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complex called RNA induced silencing complex (RISC). At the heart of RISC are the 83 
argonaute proteins, that unwind the double stranded RNA [18]. During this process one RNA 84 
strand is removed (passenger strand), while the other RNA strand (guide strand) remains 85 
within the RISC [19]. This completes the biogenesis pathway for miRNAs, as this guide 86 
strand is now the mature miRNA. This miRNA-RISC complex now has the capacity to 87 
epigenetically regulate gene expression. 88 
 89 
Function: 90 
The miRNA-RISC regulates gene expression by binding to the 3’ end of the messenger RNA 91 
(mRNA) and regulates its translation. Although not fully understood, this miRNA-RISC is 92 
hypothesized to regulate translation by two processes [20]: (1) miRNA-RISC obstructs the 93 
binding of ribosomes to the mRNA [21] and (2) deadenylation and decapping of the mRNA 94 
rendering the mRNA unstable, promoting its decay [22]. Ultimately, these two approaches 95 
suppress translation resulting in a decrease of protein output. In rare situations, there are some 96 
miRNAs that enhance translation. An example of this is miRNA miR-10a that promotes the 97 
translation of ribosomal mRNA [23]. Orom et al. (2008) speculated that this miRNA 98 
competes with a negative regulator that suppresses translation of ribosomal mRNA. 99 
The ability of miRNAs to recognize and bind to mRNA is primarily determined by its 100 
seed region, located at nucleotide positions 2 to 7 from the 5’ end of the miRNA strand [24]. 101 
It has been predicted that a single miRNA can regulate more than 200 different mRNA 102 
species [25]. Furthermore, it has been hypothesized that greater than 60% of genes are 103 
regulated by miRNAs. Consequently, miRNAs are critically involved in regulating many 104 
biological processes [26]. This makes miRNAs attractive as biomarkers or therapeutic targets, 105 
as dysregulation of miRNA expression has been linked to several diseases such as cancer and 106 
diabetes mellitus (DM) [27]. 107 
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 108 
Quantifying miRNAs 109 
 110 
There are limitations regarding miRNA detection due to inefficient RNA isolation, serum or 111 
plasma contamination by haemolysis, variable reverse transcription (RT) and polymerase 112 
chain reaction (PCR) efficiencies, inconsistent reference genes and the existence of different 113 
qPCR platforms [28]. It is still a challenge to collect and quantify extracellular miRNAs. This 114 
is due to the low concentration present in body fluids, the difficulty distinguishing between 115 
mature and immature miRNA and the presence of miRNA isoforms.  116 
Currently, the most sensitive, reproducible and gold standard method to quantify 117 
miRNAs is quantitative real-time PCR (qRT-PCR) [29]. qRT-PCR involves RT of miRNA 118 
into cDNA, before amplification and detection with specific probes. Advances have been 119 
made in detecting low amounts of miRNA in the range of approximately 7 fM [30], which is 120 
superior to other qRT-PCR based technologies. Subsequently, high-throughput qRT-PCR 121 
platforms were developed to allow rapid miRNA profiling of a large number of samples [31]. 122 
The most commonly used qRT-PCR miRNA expression profiling method is TaqMan low-123 
density array (TLDA), which is both cost-effective and high-throughput. This TLDA 124 
technology has been utilized to profile miRNAs within serum isolated from GDM patients 125 
(Table 1) [32]. 126 
Microarrays are a technology based on the hybridization of cDNA to DNA probes 127 
[28]. The approach is limited by low sensitivity, high RNA input requirement (100 ng to 1µg), 128 
and suffers from background and cross-hybridization when compared to qRT-PCR. 129 
Therefore, microarrays are not ideal for miRNA profiling, since they cannot detect highly 130 
expressed miRNAs (due to signal over saturation) or distinguish between mature and 131 
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immature miRNAs. Nevertheless, microarrays have been used as a discovery tool to identify 132 
miRNAs that are differentially expressed between GDM and normal controls [33, 34]. 133 
Next generation sequencing technology (NGS) has the advantage over other 134 
technologies, as it can identify novel miRNAs and other small RNA species [35]. NGS is 135 
more laborious than qRT-PCR and microarrays and requires a larger amount of RNA input 136 
(500 ng to 5 µg). It is possible to barcode multiple samples and sequence them simultaneously 137 
thereby reducing the costs and time. miRNA databases and bioinformatics tools are available 138 
that provide information on miRNA sequences, miRNA-mRNA target interactions, and the 139 
involvement of miRNAs in biological as well as pathological processes. NGS was utilized to 140 
identify differentially expressed miRNAs in GDM compared to normal pregnancies (Table 1) 141 
[36]. 142 
In summary, qRT-PCR is ideal for low input RNA, NGS technologies for 143 
identification of novel miRNAs, and microarrays (low sensitivity) along with NGS (high 144 
sensitivity) is utilised to screen for differentially expressed miRNAs in a large set of samples. 145 
Several researchers have compared these three technologies for miRNA quantification and 146 
concluded that each technology has its own strengths and weaknesses [37]. Deciding on 147 
which technology to use for miRNA quantification and profiling depends on the experimental 148 
design and its goals. 149 
 150 
Extracellular and intracellular miRNAs during normal and GDM pregnancies  151 
 152 
Extracellular miRNAs present in body fluids can be located within extracellular vesicles 153 
(EVs) (exosomes, microvesicles and apoptotic bodies [38]), bound to protein complexes (such 154 
as argonaute2 complexes [39]) or within high-density lipoproteins (HDL) [40]. These 155 
structures protect extracellular miRNAs from degradation, rendering them very stable in 156 
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biological fluids. Therefore, miRNAs are exciting candidates for biomarkers [41, 42]. Recent 157 
studies have produced promising results on the potential of extracellular miRNAs in blood 158 
(termed circulating miRNAs) as biomarkers that may be useful in the diagnosis of GDM (see 159 
Figure 1) [43]. 160 
The literature showed extensive studies of miRNAs in DM1 and DM2, but studies into 161 
their role in GDM is lacking. There have only been 6 studies investigating miRNAs in GDM, 162 
only 2 of which specifically investigate extracellular miRNAs within the blood (see Table 1) 163 
[32, 36]. A study by Zhao et al. (2011) reported that miR-132, miR-29a and miR-222 are 164 
decreased in serum of women with GDM [32]. A second study by Zhu et al. (2015) reported 165 
that hsa-miR-16-5p, hsa-miR-17-5p, hsa-miR-19a-3p, hsa-miR-19b-3p and hsa-miR-20a-5p 166 
are increased in the plasma of women with GDM [36]. There is no apparent correlation 167 
between these two studies with respect to the miRNAs detected. 168 
Four other studies investigated intracellular miRNAs in GDM (see Table 1) [33, 34, 169 
44, 45]. Interestingly, the studies by Zhao et al. (2011) and Shi et al. (2014) share one miRNA 170 
in common, which is miR-222 [32, 33]. However, the expression of miR-222 is not consistent 171 
between the two studies. Zhao et al. (2011) reported that miR-222 is supressed in GDM, 172 
while Shi et al. (2014) demonstrated that miR-222 was upregulated in GDM. One potential 173 
reason for this inconsistency is that different tissue types were analysed, namely serum and 174 
omental adipose tissue [32, 33]. 175 
Clearly, there is a lack of data regarding the expression of miRNAs in pregnancies 176 
complicated by GDM. However, parallels can be drawn between GDM and DM. Collares et 177 
al. (2013) investigated the differences and similarities between DM1, DM2 and GDM in 178 
peripheral blood mononuclear cells [46]. These investigators found 9 miRNAs: hsa-miR-126, 179 
hsa-miR-1307, hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-144, hsa-miR-199a-5p, hsa-miR-180 
27a, hsa-miR-29b and hsa-miR-342-3p that were shared in DM1, DM2 and GDM. 181 
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Interestingly, hsa-miR-27a and hsa-miR-29b (a miRNA sharing sequence composition to hsa-182 
miR-29a) was also detected in GDM as observed by Li et al. (2015) and Zhao et al. (2011) 183 
[32, 34]. Furthermore, Collares et al. (2013) reported that miR-222 is specific to DM2. This 184 
miRNA has also been identified in GDM studies [32, 33], contradicting this observation by 185 
Collares et al. (2013) [46]. Nevertheless, miR-222 seems to be closely linked to DM2 and 186 
GDM pathology. 187 
In addition, research detecting an increase of this miRNA within plasma of patients 188 
with DM2 further supports the previous studies investigating miR-222 [47, 48]. However, a 189 
study investigating miR-222 in plasma microparticles concluded that there was no difference 190 
between DM2 and normal controls [49]. A majority of studies have found miR-222 191 
differentially expressed in plasma between normal and GDM/DM2 patients [32, 46-48]. 192 
Consequently, this suggests that miR-222 is not located within microparticles, but within 193 
other lipid vesicle subtypes or bound to protein complexes within blood. This miRNA miR-194 
222 has been heavily investigated in cancer and has been demonstrated to regulate Kip1, a 195 
protein required for cell cycle entry and growth factor stimulation [50].  196 
With regards to GDM, miR-222 has been shown to directly target the 3’ untranslated 197 
region of ERα, a protein involved in regulating GLUT4 expression [33, 51]. Shi et al. (2011) 198 
further demonstrated that silencing of miR-222 caused an increase of ERα and GLUT4 199 
expression. Finally, insulin stimulation in miR-222 silenced cells caused an increase in 200 
GLUT4 translocation from the cytoplasm to the plasma membrane, suggesting enhanced 201 
glucose uptake [33]. This is very interesting as it means that cells with accumulated miR-222 202 
would be less receptive to insulin stimulation. Perhaps this increase in intracellular miR-222 203 
can be detected in blood, as demonstrated in the previous studies in DM [46-48]. However, 204 
Zhao et al. (2011) found that miR-222 is decreased in serum of patients with GDM [32]. 205 
Further investigations are needed to understand the role of miR-222 in GDM. 206 
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A study performing a meta-analysis on the current literature for miRNAs and DM has 207 
identified a range of circulating and tissue specific miRNAs [52]. Interestingly, miR-29a, 208 
miR-19b, miR-132, miR-16 and miR-20b were differentially expressed in DM, corroborating 209 
with studies in GDM (see Table 1) [32, 52]. Another study identifies miR-29, miR-19a, miR-210 
33a being involved in the insulin signalling pathway [53]. These miRNAs are also 211 
differentially expressed in GDM, thus are attractive therapeutic targets [34, 36, 45]. Finally, 212 
miR-103 and miR-107 have been closely connected to insulin sensitivity [54]. This previous 213 
study led to the development of a GalNac-conjugated anti-miR, targeting miR-103 and miR-214 
107 (called RG-125) by the company Regulus™. RG-125 is currently undergoing phase 1 215 
study in humans for the treatment of non-alcoholic steatohepatitis in patients with DM2. This 216 
study shows the potential for miRNAs to be used as therapeutics for metabolic disorders, such 217 
as GDM. 218 
 219 
What are exosomes?  220 
 221 
Exosomes are a member of the EVs and originate from the endosomal compartment by the 222 
fusion of multivesicular bodies with the plasma membrane [55]. Exosomes are bi-layered 223 
lipid vesicles between 40 to 120 nm in diameter, are secreted by multiple cell types, and are 224 
key players in many biological functions. Furthermore, exosomes contain both RNA 225 
(primarily miRNA) and protein. These secreted exosomes are involved in cell-to-cell 226 
communication by delivering their cargo into recipient cells. Furthermore, these secreted 227 
exosomes can be isolated from conditioned medium and body fluids (e.g. plasma, saliva, 228 
urine). Exosome isolation involves several steps including ultracentrifugation, ultrafiltration 229 
and separation by density gradient [56]. Centrifugation coupled with ultrafiltration can further 230 
enrich for exosomes by separating vesicles based on their size. Specifically, larger vesicles 231 
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such as apoptotic bodies and microvesicles can be separated from smaller vesicles such as 232 
exosomes using a 0.22µm filter [57]. Additionally, exosomes can be further purified by 233 
density using sucrose and iodixanol gradients. Another exosome isolation method mentioned 234 
in the literature is immunoisolation using magnetic beads coated with specific antibodies 235 
against exosomal proteins [58]. However, capturing exosomes with a specific exosomal 236 
antibody can be limiting when an exosome does not possess the certain marker. Furthermore, 237 
a microfluidic device has also been used for separation of exosomes from serum using micro-238 
channels [59]. Different exosome isolation techniques were also applied to obtain exosomes 239 
in GDM patients (Table 2). 240 
 It is important to note that EVs are a heterogeneous group. Its nomenclature is 241 
constantly being redefined by the scientific community [60]. A strict separation between the 242 
different vesicle types by size or biogenesis has not been established. There is still no 243 
agreement on markers (e.g. CD63, Hsp70, CD9 for exosomes) that can distinguish the 244 
different type of vesicles by its origin once they leave the cell. Furthermore, Thery et al. 245 
(2006) has investigated various exosome isolation techniques and concluded that each 246 
isolation technique lead to different yields and purities of the sample [58]. Therefore, these 247 
differences in methodologies can result in inconsistencies within downstream protein and 248 
RNA analyses. Consequently, in the growing interest of EVs as a diagnostic tool, 249 
standardization in EV isolation and analysis methodologies are required. 250 
 251 
Exosomal miRNAs during GDM pregnancies  252 
 253 
Dysregulation of miRNA expression has been linked with metabolic disorders, such as DM2 254 
and dyslipidaemia [61]. Consequently, the miRNA population within exosomes can be 255 
profiled and used as biomarkers for diseases such as GDM [62]. Consistent with this proposal, 256 
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trophoblast/cytotrophoblast derived exosomes have been used to define fetal-maternal 257 
interaction [63, 64] as well as placental dysfunction [65], which is important in GDM 258 
pathogenesis. 259 
Research into GDM and exosomes is still formative, with only 6 studies specifically 260 
focused on exosomes and GDM pathogenesis (see Table 2). Sarker et al. (2014), Salomon et 261 
al. (2016) and Nardi et al. (2016) observed an increase in exosome concentration in the 262 
maternal plasma of first trimester pregnant women. Furthermore, exosome concentrations 263 
correlated with gestational age [66-69], while the release of trophoblast-derived exosomes 264 
decreased dramatically in the third trimester [67]. Rice et al. (2015) established a link 265 
between increased exosome concentration and GDM by defining the effects of glucose 266 
concentration on exosome release and bioactivity [70]. They reported that high glucose 267 
concentrations increased the release of exosomes from first-trimester trophoblast cells and the 268 
capacity of exosomes to induce the release of cytokine mediators from target cells. 269 
 A subsequent study by Salomon et al. (2016), reported the differential release of pro-270 
inflammatory cytokines (GM-CSF, IL-4, IL-6, IL-8, IFN-y and TNF-α) from endothelial cells 271 
when treated with placental exosomes derived from women with GDM [68]. These data 272 
warrant further investigation to elucidate the intracellular mechanisms by which glucose 273 
regulates exosome biogenesis, packaging and bioactivity, and how this contributes to the 274 
aetiology and progression of GDM.  275 
Further research is necessary to identify miRNAs specific for GDM in placental or 276 
maternal derived exosomes in blood. It is known that the chromosome 19 miRNA cluster 277 
(C19MC) is exclusively expressed in the placenta [64]. Recently, Almohammadi et al. (2016) 278 
identified that the abundance of miR-518a-5p, miR-518b, miR-518c, miR-518e, miR-520c-3p 279 
and miR-525-5p (members of the C19MC region) in placental exosomes isolated from 280 
women with GDM is increased when compared to women with normal pregnancies [71]. 281 
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Furthermore, Donker et al. (2012) also investigated the expression C19MC region under 282 
placental hypoxia, which is implicated in fetal growth restriction [64]. Donker et al. (2012) 283 
found that the C19MC miRNA region is not differentially expressed in placenta hypoxia 284 
compared to control, but did observe a downregulation of miR-520c-3p. Furthermore, this 285 
miRNA was found to be elevated within maternal plasma of GDM patients. These 286 
aforementioned results suggests a role of miR-520c-3p in placental oxygen supply [71]. 287 
However, the role of the entire C19MC region in GDM pathogenesis remains to be 288 
elucidated. 289 
 290 
Conclusion  291 
 292 
The early diagnosis of GDM during the first trimester of pregnancy is critical in preventing 293 
complications for both the mother and the fetus. Current diagnostic methods fail to identify 294 
GDM early, which leads to the urgent need of research and development for new diagnostic 295 
tools. The measurement of extracellular miRNAs encapsulated in exosomes within blood 296 
holds great promise as a reliable and accurate diagnostic tool for GDM. Using methods such 297 
as qRT-PCR and NGS, these extracellular miRNAs have been demonstrated to be 298 
differentially expressed in women with GDM. Currently, research into exosomal miRNAs in 299 
GDM has not been sufficient. In addition, there is no apparent correlation between studies 300 
investigating extracellular miRNAs and GDM. Therefore, additional research is required to 301 
understand the role of exosomes and extracellular miRNA in GDM, how these contribute to 302 
the aetiology of GDM, and the potential for using exosomes and extracellular miRNAs as 303 
interventions for GDM. 304 
  305 
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Table 1: Tabulation of miRNAs in GDM compared to normal controls. 527 
Publication Sample 
miRNA 
upregulated in 
GDM 
miRNA 
downregulated 
in GDM 
Detection technique 
[32] Serum  
miR-132, miR-
29a, miR-222 
Discovery = TaqMan 
low density array 
Validation = Real-
time PCR 
[36] Plasma 
hsa-miR-16-
5p, hsa-miR-
17-5p, hsa-
miR-19a-3p, 
hsa-miR-19b-
3p, hsa-miR-
20a-5p 
 
Discovery = Ion 
Torrent (Sequencing) 
Validation = Real-
time PCR 
[34] Placental tissue miR-508-3p 
miR-27a, miR-
9, miR-137, 
miR-92a, miR-
33a, miR-30d, 
miR-362-5p 
and miR-502-
5p 
Discovery = Agilent 
Human miRNA 
Microarray 
Validation = Real-
time PCR 
[45] Placental tissue miR-518d  Real-time PCR 
[33] 
Omental 
adipose tissue 
miR-222  
Discovery = AFFX 
miRNA expression 
chips 
Validation = Real-
time PCR 
[44] 
Primary 
HUVEC 
miR-101  Real-time PCR 
  528 
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Table 2: Exosomes and exosomal miRNAs in GDM pathogenesis  529 
Publicati
on 
Sample 
GDM 
linked 
pathogene
sis  
Exosome 
isolation 
method 
Number of 
exosomes 
miRNA 
Detectio
n 
techniq
ue 
[71] 
Plasma 
(trophobl
ast cells) 
To be 
determined 
Differential 
and buoyant 
density 
centrifugati
on 
 
 
↑miR-518a-
5p, miR-
518b, miR-
518c, miR-
518e, miR-
520c-3p and 
miR-525-5p 
(GDM 
patients vs 
normal 
pregnancy) 
qRT-
PCR 
[66, 67, 
69] 
Maternal 
or fetal 
plasma 
exosomes 
Exosomes 
might play 
a role in 
feto-
maternal 
interaction 
and 
placenta 
developme
nt 
[66, 67] 
Differential 
and buoyant 
density 
centrifugati
on using a 
sucrose 
continuous 
gradient 
ultrafiltratio
n. 
 
[69] 
ExoQuick™ 
or 
ultracentrifu
gation 
 
Total 
exosome 
Increased 50-
fold during 
pregnancy 
(pregnancy vs 
non-
pregnant). 
Placental 
exosome 
number 
decline during 
pregnancy 
- - 
[68] 
Maternal 
periphera
l plasma 
exosomes 
Bioactive 
(cytokine 
release) 
and 
promote 
cell 
migration.  
Differential 
and buoyant 
density 
centrifugati
on using a 
sucrose 
continuous 
ultrafiltratio
n 
- - - 
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 530 
  531 
[70] 
First 
trimester 
trophobla
st cells 
Extracellul
ar milieu 
regulate 
the release 
and 
bioactivity 
of 
exosomes 
Differential 
and buoyant 
density 
centrifugati
on 
 
Release of 
exosomes 
increased 
with higher 
glucose and 
low oxygen 
tension. High 
oxygen 
tension 
decreased 
exosome 
release 
- - 
[64] 
Primary 
human 
trophobla
st 
Placenta 
hypoxia 
(fetal 
growth 
restriction) 
Ultracentrif
ugation and 
ultrafiltratio
n 
 
No effect on 
other 
CM19MC 
miRNAs 
↓miR-520c-
3p 
qRT-
PCR 
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Figure Legend 532 
 533 
Figure 1: Overall summary of extracellular and intracellular miRNAs as biomarkers for 534 
GDM. The placenta provides the exchange of nutrients between maternal and fetal blood 535 
supply during pregnancy. The mother and fetus release exosomes containing miRNA and 536 
proteins, which allows cell-to-cell communication via the delivery of their cargo into recipient 537 
cells. In addition, miRNAs can be bound to protein and HDL complexes. Extracellular and 538 
intracellular miRNAs can be isolated from plasma or tissue/cells, respectively. After isolation, 539 
miRNAs can be quantified by methods including: qRT-PCR, NGS and microarrays. Using 540 
these methods, the differential expression of candidate miRNAs between GDM and normal 541 
pregnancies can be established and putative biomarkers of GDM (e.g. miR-222 and C19MC 542 
miRNA region) identified and validated. 543 
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